<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, nelfinavir mesylate, the mesylate salt of the antiviral drug nelfinavir which has been characterized as a HIV-1 protease inhibitor (
 <xref rid="B142" ref-type="bibr">Patick et al., 1996</xref>; 
 <xref rid="B123" ref-type="bibr">Markowitz et al., 1998</xref>), was found to have antiviral activity against HSV-1 and other herpesviruses and to inhibit the maturation and export of viral particles (
 <xref rid="B87" ref-type="bibr">Kalu et al., 2014</xref>). As a consequence, nelfinavir mesylate is currently being assessed in a clinical study for the treatment of patients with Kaposiâ€™s sarcoma, as well as its potential effectivity activity against HSV-1 and HSV-2, which is a tertiary goal in this study (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> Identifier: NCT03077451).
</p>
